<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(AMENDMENT NO. 1)
UNDER THE SECURITIES AND EXCHANGE ACT OF 1934
RENEX CORP.
- --------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
759683105
----------------------------------------------------------
(CUSIP Number)
ADAM H. GOLDEN, ESQ.
KAYE, SCHOLER, FIERMAN, HAYS & HANDLER, LLP
425 PARK AVENUE
NEW YORK, NEW YORK 10022
(212) 836-7016
----------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
FEBRUARY 1, 2000
----------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box: / /.
(continued on following pages)
(Page 1 of 9)
<PAGE> 2
SCHEDULE 13D
- -------------------------- -----------------------------
CUSIP NO. 759683105 Page 2 of 9
- -------------------------- -----------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
RC ACQUISITION CORP.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) /X/
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC, BK
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(D) OR 2(E) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE ORGANIZATION
FLORIDA
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
0
SHARES -------------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY 0
-------------------------------------------------------------
OWNED BY 9 SOLE DISPOSITIVE POWER
0
EACH -------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
REPORTING 0
PERSON WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.0%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- --------------------------------------------------------------------------------
<PAGE> 3
SCHEDULE 13D
- -------------------------- -----------------------------
CUSIP NO. 759683105 Page 3 of 9
- -------------------------- -----------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
NATIONAL NEPHROLOGY ASSOCIATES, INC.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)/X/
(b)/ /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC, BK
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE ORGANIZATION
DELAWARE
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
0
SHARES -------------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY 100
-------------------------------------------------------------
OWNED BY 9 SOLE DISPOSITIVE POWER
0
EACH -------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
REPORTING 100
PERSON WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
100
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
100.0%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- --------------------------------------------------------------------------------
<PAGE> 4
SCHEDULE 13D
- -------------------------- -----------------------------
CUSIP NO. 759683105 Page 4 of 9
- -------------------------- -----------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J.W. CHILDS EQUITY PARTNERS II, L.P.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)/X/
(b)/ /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC, BK
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE ORGANIZATION
DELAWARE
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
0
SHARES -------------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY 100
-------------------------------------------------------------
OWNED BY 9 SOLE DISPOSITIVE POWER
0
EACH -------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
REPORTING 100
PERSON WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
100
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
100.0%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
- --------------------------------------------------------------------------------
<PAGE> 5
SCHEDULE 13D
- -------------------------- -----------------------------
CUSIP NO. 759683105 Page 5 of 9
- -------------------------- -----------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
J.W. CHILDS ASSOCIATES, INC.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)/X/
(b)/ /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC, BK
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE ORGANIZATION
DELAWARE
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
0
SHARES -------------------------------------------------------------
8 SHARED VOTING POWER
BENEFICIALLY 100
-------------------------------------------------------------
OWNED BY 9 SOLE DISPOSITIVE POWER
0
EACH -------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
REPORTING 100
PERSON WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
100
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES / /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
100.0%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- --------------------------------------------------------------------------------
<PAGE> 6
ITEM 1. SECURITY AND ISSUER.
This statement on Schedule 13D relates to the common stock, par
value $0.001 per share (the "Common Stock"), of Renex Corp., a Florida
Corporation (the "Issuer"), beneficially owned by RC Acquisition Corp., a
Florida corporation ("Merger Sub"), National Nephrology Associates, Inc., a
Delaware corporation ("Parent"), J.W. Childs Equity Partners II, L.P., a
Delaware limited partnership ("JWCEP") and J.W. Childs Associates, Inc., a
Delaware corporation ("JWCA"). JWCA, together with JWCEP, Parent and Issuer are
the "Reporting Persons." Effective as of February 1, 2000, as a result of the
transactions more fully described in Item 4 herein, as amended, Merger Sub was
merged with and into the Issuer and is no longer a Reporting Person. The
Reporting Persons hereby file this Amendment No. 1 (this "Amendment No. 1") to
the Schedule 13D filed on January 7, 2000 (the "Schedule 13D").
Unless otherwise indicated, all capitalized terms not otherwise
defined herein shall have the same meanings as those set forth in the Schedule
13D.
ITEM 2. IDENTITY AND BACKGROUND.
This Amendment No. 1 is being filed by the Reporting Persons and the
information contained herein supplements the information contained in the
Schedule 13D.
As a result of the transactions more fully described in Item 4
herein, as amended, Merger Sub was merged with and into the Issuer (the
"Merger") and Merger Sub's separate corporate existence terminated, Merger Sub
ceased to be the beneficial owner of more than five percent of Common Stock, and
thus ceased to be a Reporting Person.
ITEM 4. PURPOSE OF TRANSACTION.
As previously reported in the Schedule 13D, Parent, Merger Sub and
the Issuer entered into an Agreement and Plan of Merger (the "Merger
Agreement"), dated as of December 28, 1999. The Merger Agreement was approved
and adopted by the board of directors of the Issuer at a meeting held on
December 27, 1999. Pursuant to the Merger Agreement, Merger Sub commenced a
tender offer (the "Offer") for all of the outstanding shares of Common Stock of
the Issuer at a purchase price of $10.00 per share of Common Stock without
interest. The purpose of the Merger and the Offer was to enable Parent, through
Purchaser, to acquire control of, and the entire equity interest in, the Issuer.
The Offer was consummated on February 1, 2000, and as of such date, 7,393,055
shares of Common Stock, or approximately 86.3% of the outstanding shares of
Common Stock, were purchased by Merger Sub pursuant to the Offer. Because Merger
Sub acquired greater than 80% of the shares of Common Stock on a fully-diluted
basis, Florida law permitted Merger Sub to effect the Merger without a
shareholders' meeting and without the approval of or prior notice to the other
shareholders of the Issuer. The Merger was consummated pursuant to the Merger
Agreement on February 1, 2000 (the "Effective Time"). In connection with the
Merger, each share of the common stock, par value $0.001 per share, of the
Issuer was
Page 6 of 9
<PAGE> 7
converted into the right to receive $10.00 in cash without interest. In
connection with the Merger, Parent also refinanced certain of its outstanding
indebtedness.
At the Effective Time, each of the 100 outstanding shares of common
stock of Merger Sub were converted into a share of common stock of the Issuer as
the surviving corporation in the Merger. As a result, as of the Effective Time,
the Issuer became a wholly owned subsidiary of Parent.
Following the Merger, the Issuer applied to have the Common Stock
delisted from the Nasdaq National Market and the Issuer filed a Form 15 with the
Securities and Exchange Commission suspending the Issuer's duty to file reports
under Section 15(d) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act") and seeking to deregister the Common Stock under the Exchange
Act.
As previously reported in the Schedule 13D, contemporaneous with
entering into the Merger Agreement, Merger Sub and Parent entered into a
shareholders agreement, dated as of December 28, 1999 (the "Shareholders
Agreement"), with the directors and executive officers of the Issuer. The
Shareholders Agreement, terminated according to its terms upon the consummation
of the Merger at the Effective Time.
As of the Effective Time, and pursuant to the Merger Agreement, the
sole director of the Issuer (the "Board") became Leif Murphy, Executive Vice
President and Chief Financial Officer of the Parent. Promptly following the
Effective Time, Mr. Murphy was removed as a director and the following persons
were appointed to the Board of Directors: Dr. Jerome S. Tannenbaum, Chairman
and Chief Executive Officer of Parent; Dr. Jeffrey L. Hymes, Director,
President and Chief Medical Officer of Parent; Joseph A. Cashia, Executive Vice
President and Chief Operating Officer of Parent; and M. Stephen Harrison,
Executive Vice President, New Business Development of Parent. The composition
of the Board is subject to change from time to time, but representatives or
employees of the Reporting Persons are expected to constitute a majority of the
Board. In that capacity, such persons will be consulted, and will vote, on
matters that are presented to the Board, including sales of assets,
extraordinary corporate transactions and changes to the Issuer's
capitalization, dividend policy, business or corporate structure. The officers
of Purchaser immediately prior to the Effective Time became the officers of the
Issuer after the Effective Time.
At the Effective Time and pursuant to the Merger Agreement, the
articles of incorporation of Merger Sub became the articles of incorporation of
the Issuer, and the by-laws of Merger Sub became the by-laws of the Issuer.
The preceding summary of certain provisions of the Merger Agreement
is not intended to be complete and is qualified in its entirety by reference to
the full text of such agreements, copies of which have previously been filed as
exhibits to the Schedule 13D, and incorporated therein by reference.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
Page 7 of 9
<PAGE> 8
(a) As of February 1, 2000, Parent beneficially and directly owns, and
the other Reporting Persons may be deemed to own beneficially and
indirectly, 100 shares of Common Stock, or 100.0% of the shares of
Common Stock issued and outstanding.
(b) Each Reporting Person shares the power to vote or direct the vote
and dispose or direct the disposition of shares of Common Stock
beneficially owned by such Reporting Person as indicated in pages 2
through 5 above.
(c) Except as described in Item 4 hereof, no transactions in the Common
Stock were effected by the Reporting Persons, or, to the best
knowledge of any of the Reporting Persons, any of the persons listed
on Schedules I or II hereto, during the 60-day period preceding
February 1, 2000.
(d) No person other than the Reporting Persons has the right to receive
dividends from, or the proceeds from the sale of, the shares of
Common Stock beneficially owned by such Reporting Persons.
(e) Pursuant to the Merger, Merger Sub was merged with and into the
Issuer and Merger Sub's separate corporate existence terminated,
Merger Sub ceased to be the beneficial owner of more than five
percent of the Common Stock, and thus ceased to be a Reporting
Person.
Page 8 of 9
<PAGE> 9
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
I certify the information set forth in this statement is true, complete and
correct.
Dated as of: February 2, 2000
RC ACQUISITION CORP.
By: /s/ Leif Murphy
-----------------------------------------
Name: Leif Murphy
Title:Executive Vice President and Chief
Financial Officer
NATIONAL NEPHROLOGY ASSOCIATES, INC.
By: /s/ Leif Murphy
-----------------------------------------
Name: Leif Murphy
Title:Executive Vice President and Chief
Financial Officer
J.W. CHILDS EQUITY PARTNERS II, L.P.
By: J.W. Childs Advisors II, L.P., its general
partner
By: J.W. Childs Associates, L.P., its
general partner
By: J.W . Childs Associates, Inc.,
its general partner
By: /s/ Edward Yun
-----------------------------------------
Name: Edward Yun
Title:Vice President
J.W. CHILDS ASSOCIATES, INC.
By: /s/ Edward Yun
-----------------------------------------
Name: Edward Yun
Title:Vice President
Page 9 of 9
